Program Description
In recent decades, significant progress has been made in the management of diabetes with novel medications, insulin formulations, and use of technology. However, people with diabetes continue to experience long-term microvascular complications, such as retinopathy and nephropathy. Nephropathy occurs in more than 40% of people with diabetes and is the leading cause of chronic kidney disease (CKD) worldwide; therefore, prevention and optimal management of CKD in diabetes remains a key treatment target. Pharmacists need to be familiar with screening parameters for the early identification and treatment of CKD in patients with diabetes because aggressive management of comorbidities and complications may prevent progression to end-stage renal disease. Optimal management has the potential for cost savings, as progression of CKD and cardiovascular events lead to increased healthcare resource utilization and remain a leading driver of costs for patients with diabetes. The expert panelists will discuss the current landscape of CKD prevention and management including renal protective strategies and emerging treatments.
Target Audience: Managed care pharmacists
Type of Activity: Application
Release date: November 4, 2021
Expiration date: November 4, 2022
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the epidemiology of diabetes and chronic kidney disease (CKD) and the pathology of kidney disease in this population, along with the drivers of CKD progression
- Interpret the current clinical guidelines and data for CKD in type 2 diabetes along with medication recommendations and emerging treatment options aimed at addressing the gaps in care
- Examine the economic and clinical burden of diabetic CKD and opportunities for managed care interventions to improve costs and patient outcomes
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
